All Stories

  1. Clinical safety and tolerability of tedizolid phosphate in the treatment of acute bacterial skin and skin structure infections

    Article • Expert Opinion on Drug Safety, March 2018, Taylor & Francis

    Shawn Daniel Flanagan

  2. Stability of crushed tedizolid phosphate tablets for nasogastric tube administration

    Article • Critical Care, January 2015, Springer Science + Business Media

    Shawn Daniel Flanagan

  3. Nonclinical and Pharmacokinetic Assessments To Evaluate the Potential of Tedizolid and Linezolid To Affect Mitochondrial Function

    Article • Antimicrobial Agents and Chemotherapy, October 2014, ASM Journals

    Shawn Daniel Flanagan, Professor Edward E McKee

  4. Tedizolid Population Pharmacokinetics, Exposure Response, and Target Attainment

    Article • Antimicrobial Agents and Chemotherapy, August 2014, ASM Journals

    Shawn Daniel Flanagan

  5. Pharmacokinetics of Tedizolid in Subjects with Renal or Hepatic Impairment

    Article • Antimicrobial Agents and Chemotherapy, August 2014, ASM Journals

    Shawn Daniel Flanagan

  6. Single‐ and Multiple‐Dose Pharmacokinetics and Absolute Bioavailability of Tedizolid

    Article • Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, July 2014, Wiley

    Shawn Daniel Flanagan

  7. Absorption, Distribution, Metabolism, and Excretion of the Novel Antibacterial Prodrug Tedizolid Phosphate

    Article • Drug Metabolism and Disposition, May 2014, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Shawn Daniel Flanagan

  8. 925

    Article • Critical Care Medicine, December 2013, Wolters Kluwer Health

    Shawn Daniel Flanagan

  9. Pharmacokinetics of Tedizolid Following Oral Administration: Single and Multiple Dose, Effect of Food, and Comparison of Two Solid Forms of the Prodrug

    Article • Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, August 2013, Wiley

    Shawn Daniel Flanagan

  10. In Vitro,In Vivo, and Clinical Studies of Tedizolid To Assess the Potential for Peripheral or Central Monoamine Oxidase Interactions

    Article • Antimicrobial Agents and Chemotherapy, April 2013, ASM Journals

    Shawn Daniel Flanagan

  11. Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing

    Article • Clinical Pharmacokinetics, January 2011, Springer Science + Business Media

    Shawn Daniel Flanagan

  12. Safety, Tolerability, QTc Evaluation, and Pharmacokinetics of Single and Multiple Doses of Enzastaurin HCl (LY317615), a Protein Kinase C-β Inhibitor, in Healthy Subjects

    Article • The Journal of Clinical Pharmacology, September 2007, Wiley

    Shawn Daniel Flanagan

  13. Biological activity of AC3174, a peptide analog of exendin-4

    Article • Regulatory Peptides, June 2007, Elsevier

    Shawn Daniel Flanagan

  14. Clinical Pharmacokinetics of Alamifovir and Its Metabolites

    Article • Antimicrobial Agents and Chemotherapy, May 2005, ASM Journals

    Shawn Daniel Flanagan

  15. Contributions of Saturable Active Secretion, Passive Transcellular, and Paracellular Diffusion to the Overall Transport of Furosemide Across Adenocarcinoma (Caco-2) Cells

    Article • Journal of Pharmaceutical Sciences, April 2002, Elsevier

    Shawn Daniel Flanagan

  16. Comparison of Furosemide and Vinblastine Secretion from Cell Lines Overexpressing Multidrug Resistance Protein (P-Glycoprotein) and Multidrug Resistance-Associated Proteins (MRP1 and MRP2)

    Article • Pharmacology, January 2002, Karger Publishers

    Shawn Daniel Flanagan